TriangleNCT04172467 · OUTCOME
Guideline Adherence (GLAD)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Median study observation period of 18.2 months
What was measured
For SID, immunoglobulin substitution (IgRT) is mandatory only for patients with an IgG level \< 4g/l (or IgG subclass deficiency) and additionally more than 3 infections or a severe infection (≥ grade 3) and is optional (may be appropriate) if IgG level \< 4g/l and/or 1-3 less severe infections (≤ grade 2). IgRT is not indicated if patients do not fulfil either condition. Scoring system: GLAD-Score 2: full guideline adherence GLAD-Score 1: deviations in dose or interval (+/- 10%) or a late start of IgRT (\>28 days after a severe infection (≥ grade 3). GLAD-Score 0: IgRT without indication (overuse) or omitted IgRT despite recommendation (underuse). Likewise, 0 points were awarded if both the dose and the interval deviated from the GL recommendations (e.g. underdosed single dose) or if IgRT was not started until more than 3 months after hypogammaglobulinemia and at least one severe infection.
Groups in this outcome
Non-interventional Retrospective Observational Study.
This was a retrospective sample analysis representative for practices and hospitals in Germany. The treatments and infection data were collected from patients with chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM). GL adherence (GLAD) was analysed.
| Group | Source count |
|---|---|
| Non-interventional Retrospective Observational Study. | 1086 |
Reported measurements
Source class 1
GLAD-Score 2
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Non-interventional Retrospective Observational Study. | 889 | Not reported | Not reported | Not reported | Not reported |
GLAD-Score 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Non-interventional Retrospective Observational Study. | 75 | Not reported | Not reported | Not reported | Not reported |
GLAD-Score 0
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Non-interventional Retrospective Observational Study. | 122 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 889
- title
- GLAD-Score 2
- measurements
- group Id
- OG000
- value
- 75
- title
- GLAD-Score 1
- measurements
- group Id
- OG000
- value
- 122
- title
- GLAD-Score 0
- denoms
- counts
- group Id
- OG000
- value
- 1086
- units
- Participants
- description
- For SID, immunoglobulin substitution (IgRT) is mandatory only for patients with an IgG level \< 4g/l (or IgG subclass deficiency) and additionally more than 3 infections or a severe infection (≥ grade 3) and is optional (may be appropriate) if IgG level \< 4g/l and/or 1-3 less severe infections (≤ grade 2). IgRT is not indicated if patients do not fulfil either condition. Scoring system: GLAD-Score 2: full guideline adherence GLAD-Score 1: deviations in dose or interval (+/- 10%) or a late start of IgRT (\>28 days after a severe infection (≥ grade 3). GLAD-Score 0: IgRT without indication (overuse) or omitted IgRT despite recommendation (underuse). Likewise, 0 points were awarded if both the dose and the interval deviated from the GL recommendations (e.g. underdosed single dose) or if IgRT was not started until more than 3 months after hypogammaglobulinemia and at least one severe infection.
- groups
- description
- This was a retrospective sample analysis representative for practices and hospitals in Germany. The treatments and infection data were collected from patients with chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM). GL adherence (GLAD) was analysed.
- id
- OG000
- title
- Non-interventional Retrospective Observational Study.
- param Type
- COUNT_OF_PARTICIPANTS
- reporting Status
- POSTED
- time Frame
- Median study observation period of 18.2 months
- title
- Guideline Adherence (GLAD)
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice